FDA Gives Fungus-Finding Lung Tests a Less Bureaucratic Path
Published Date: 6/13/2025
Rule
Summary
The FDA is officially putting devices that detect fungal DNA in lung samples into a safer, easier-to-manage category called Class II. This change helps make sure these devices work well and are safe, while also speeding up patient access to new tech by cutting red tape. The new rules took effect on June 13, 2025, and could save companies time and money by simplifying approval steps.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Reclassified fungal-DNA lung tests to Class II
The FDA officially classified devices that detect and identify fungal nucleic acids directly in respiratory specimens as Class II (special controls), effective June 13, 2025 (classification applicable November 29, 2017). The agency says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access to these diagnostic tests by reducing regulatory burdens.
Easier regulatory path for future devices
Because the device was classified into Class II via the De Novo process, it can serve as a predicate device for future devices of the same type, allowing other sponsors to use the 510(k) premarket notification pathway instead of De Novo or premarket approval; the FDA says this reduces regulatory burdens and can speed access to new devices.
New special-control testing and labeling rules for manufacturers
Manufacturers of these fungal-nucleic-acid respiratory tests must meet Class II special controls in labeling and design verification/validation. Labeling must include detailed device description, instrument requirements, ancillary reagents, methodology, analytical performance data (including limit of detection, inclusivity, reproducibility, interference, cross-reactivity, carryover/cross-contamination, and specimen stability), interpretation guidance, and a statement that negative results do not rule out infection. Clinical and analytical validation must include prospective clinical studies with predefined statistical plans and documentation of device software and data-processing methods.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-10767, Special Local Regulation; 4th of July Fireworks, Lower East River & Upper New York Bay, Manhattan and Brooklyn, NY
On July 4, 2025, the Coast Guard will block off parts of the Lower East River and New York Harbor to keep boats away from the fireworks show for safety. No boats can enter the fireworks barge area from 5:30 p.m. to 11:30 p.m., with four special viewing zones set up for spectators. This temporary rule helps everyone enjoy the 4th of July fireworks safely without any extra fees or long delays.
Next: 2025-10787, Medical Devices; Immunology and Microbiology Devices; Classification of the Cellular Analysis System for Multiplexed Antimicrobial Susceptibility Testing
The FDA is officially putting the cellular analysis system for multiplexed antimicrobial susceptibility testing into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps companies bring these devices to patients faster and safer, starting June 13, 2025. Labs and medical device makers will benefit from clearer guidelines and smoother approval processes without extra costs.